Moderna
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
MRNA Key Statistics
MRNA News
Loading... Loading... Moderna Inc MRNA shares are trading higher Wednesday after the company announced an ongoing collaboration with OpenAI. What To Know: Mod...
Messenger RNA-based vaccine developer Moderna (NASDAQ:MRNA) has partnered with OpenAI to deploy San Francisco-based AI firm's ChatGPT Enterprise across its busi...
Loading... Loading... Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development o...
Analyst ratings
48%
of 25 ratingsMore MRNA News
carmengabriela Shares in Moderna (NASDAQ:MRNA), maker of the breakthrough mRNA shot against Covid-19, jumped to a three-month high this month [April 2024] afte...
Moderna (NASDAQ:MRNA) closed in green and snapped an eight-day losing streak after having lost 4% over the last eight trading sessions. Shares of the pharmaceu...
With a price-to-sales (or "P/S") ratio of 5.7x Moderna, Inc. ( ) may be sending very bullish signals at the moment, given that almost half of all the Biotechs c...
In the last year, many Moderna, Inc. (NASDAQ:MRNA) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whet...
The latest trading session saw Moderna (MRNA) ending at $101.41, denoting a -0.58% adjustment from its last day's close. The stock's change was more than the S&...
Moderna (NASDAQ:MRNA) shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost ab...
Moderna (MRNA) stock surged — and then tumbled — in mid-April after the company unveiled early-stage test results for its Merck (MRK)-partnered cancer vaccine....